Starten Sie Ihre Suche...


Durch die Nutzung unserer Webseite erklären Sie sich damit einverstanden, dass wir Cookies verwenden. Weitere Informationen

III. Medizinische Klinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Forschungsprojekte
Ergebnisse pro Seite:  10

2024 - 2026

Development of a KRASG12V targeting TCRmimic-bispecific T cell engager (BiTE) to improve immunotherapy in non-small cell lung cancer (NSCLC)
  • Benedikt J. Lohnes,
  • PD Dr. Udo F. Hartwig

2024 - 2031

CAR-T-Zell-Behandlung für unbehandeltes Hochrisiko-MANtle-Zell-Lymphom (#1462)
  • Dr. Eva Wagner-Drouet

2024

First-in-Human Clinical Study with RNA-Immunotherapy Combination of IVAC-W-bre1-uID and IVAC_M_uID for Individualized Tumour Therapy in Triple Negative Breast Cancer Patients
  • Univ.-Prof. Dr. med. Marcus Schmidt

2024 - 2022

A Randomized Open Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared To Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
  • Dr. med. Markus Munder,
  • Prof. Dr. med. Georg Heß

2023 - 2040

An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas (DAREON™-5) (#1472)
  • Dr. Jürgen Alt

2023 - 2040

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation (SNDX-5613-0700) (#1456)
  • Univ.-Prof. Dr. Michael Kühn

2023 - 2040

A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous BI 764532 in combination with topotecan for the treatment of patients with small cell lung cancer (DAREONTM-9) (#1508)
  • Dr. Jürgen Alt

2023 - 2040

A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (#1417)
  • Dr. Marius Fried

2023 - 2040

An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors (INSIGHT) (#1493)
  • Dr. Jürgen Alt

2023 - 2040

Venetoclax in combination with the BTK inhibitor Ibrutinib and rituximab or conventional chemotherapy (bendamustine) and ibrutinib and rituximab in patients with treatment naïve Mantle Cell Lymphoma not eligible for high dose therapy - The European Mantle Cell Lymphoma Elderly III-Trial (#1281)
  • Univ.-Prof. Dr. Georg Hess